Current stock page

Stock Analysis

Travere Therapeutics, Inc. (TVTX) Stock Analysis

Travere Therapeutics, Inc. (TVTX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

TVTX Stock Analysis Summary

Travere Therapeutics, Inc. (TVTX) currently has an AIQ Score of 64/100, indicating a neutral setup. Value is the strongest factor at 69/100. Risk is the weakest current factor at 55/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

TVTX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$50.65
AIQ Score64/100
Overall ViewNeutral
Technical Analysis ConsensusSell
Market Cap$4.79B
P/E Ratio (TTM)-32.47
Forward P/E—
EPS (Q3 FY2026)-$0.55
Revenue (Q3 FY2026)$224.56M
Dividend Yield (TTM)0.00%
Beta1.3
Volume708.2K
52-week range$22.59-$68.73
RSI 1443.94
50-Day SMA$55.93
200-Day SMA$47.68
Analyst Price Target$89.00
Next EarningsFeb 18, 2027
As of Nov 13, 2026 · Market close

TVTXTravere Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$50.65−$0.91 (−1.76%)

Latest quote

  • Momentum
    67
  • Value
    69
  • Quality
    63
  • Risk resilience
    55
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

TVTX Stock Analysis Summary

Travere Therapeutics, Inc. (TVTX) currently has an AIQ Score of 64/100, indicating a neutral setup. Value is the strongest factor at 69/100. Risk resilience is the weakest current factor at 55/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, TVTX has AIQ Score of 64/100 with Value base of 69/100 and fading Risk resilience at 55/100. Wait for component alignment before adding exposure.

Healthcare · -1.76% stock move · TVTX classified in Biotechnology.

Current Evidence

NeutralTVTX is in a neutral AIQ regime; Value is the strongest visible factor at 69/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is TVTX Bullish or Bearish Right Now?

TVTX currently has a neutral overall setup. Value is the strongest factor at 69/100, while Risk Resilience is weakest at 55/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 67/100.
  • - Analyst target implies +75.72% upside from the latest quote.
Bear Case
  • - Technical consensus has more sell votes than buy votes (25 vs 11).

Current Consensus

TVTX's Technical Analysis Consensus is currently Sell, with 11 buy, 10 neutral, and 25 sell votes. TVTX's 14-day RSI is 43.94, which places the stock in a weaker momentum range. TVTX's beta is 1.3, indicating greater market sensitivity than the broad market.

Signal Confidence
Moderate agreement

What Changed in TVTX?

The largest recent change in TVTX is Momentum moving down by 2.0 points over the available 7-day comparison window. Value remains the strongest visible factor.

AIQ Score
-1.0
Momentum
-2.0
Quality
+0.0
Risk
+0.0

What Would Change the TVTX Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

TVTX Decision Framework

Public evidence layers, setup checks, and risk context for Travere Therapeutics, Inc..

Travere Therapeutics, Inc. (TVTX) Stock Analysis

Travere Therapeutics, Inc. has an AIQ Score of 64/100 in a Neutral regime. Value is strongest at 69/100. Beta is 1.3, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextTVTX is in a Neutral AIQ regime with score 64/100.
Signal ConflictThe primary conflict is that value leads at 69/100 while risk lags at 55/100.
Factor EvidenceMomentum 67/100 · Value 69/100 · Quality 63/100 · Risk 55/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Value is the strongest factor at 69/100.

TimingPass

Momentum is 67/100 and RSI (14) is 43.9.

Regime fitWait

TVTX is in a Neutral regime at 64/100.

Risk controlWait

Risk factor is 55/100 with beta 1.3 and annual volatility 62.28%.

ConflictPass

Current conflict: value leads at 69/100 while risk lags at 55/100.

AIQ Score
64/100
Price
$50.65
Beta
1.3
RSI (14)
43.9

TVTX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

TVTX Fundamentals

TVTX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$224.56M
Net income
-$52.34M
Free cash flow
$98.2M
View full TVTX fundamental analysis

TVTX Technical Analysis

TVTX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Sell
RSI 14
43.94
Price vs SMA-50
-9.44%
View full TVTX technical analysis

TVTX Stock Catalysts

Track TVTX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 18, 2027
Analyst target
$89.00
News items
5
View TVTX earnings and stock catalysts

TVTX Dividend Analysis

TVTX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View TVTX dividend history and analysis

TVTX Financial Data

TVTX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$224.56M
EPS
-$0.55
Periods
8
View TVTX financials

TVTX Risk Analysis

TVTX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.3
Risk score
55/100
1Y volatility
62.28%
View TVTX risk analysis

TVTX Stock News

TVTX stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read TVTX stock news

TVTX vs Biotechnology Peers

Current peer cohort: TVTX · TWST · TYRA · URGN · UTHR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
TVTX
Current stock
64/10069/10067/10055/1000.8762.28%Current
TWST
Twist Bioscience Corporation
64/10058/10084/10032/1001.9484.18%TVTX vs TWST
TYRA
Tyra Biosciences, Inc.
49/100—27/10045/1000.6567.91%TVTX vs TYRA
URGN
UroGen Pharma Ltd.
53/10064/10040/10040/1000.3961.94%TVTX vs URGN
UTHR
United Therapeutics Corporation
76/10078/10068/10083/1000.7635.02%TVTX vs UTHR
Pairwise Compare links: TWST · TYRA · URGN · UTHRTVTX vs TWSTTVTX vs TYRATVTX vs URGNTVTX vs UTHRCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a TVTX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for TVTX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-32.47
As of Nov 13, 2026
Revenue growth
36.22%
Gross margin
94.72%
Current debt / equity
27.28
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$224.56M
Quarter net income
-$52.34M
Quarter free cash flow
$98.2M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Mixed
RSI 14
43.94
MACD
-1.09

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
55/100
Beta
1.3
Annual volatility
62.28%
Max drawdown
-33.49%

TVTX Stock FAQ

What is TVTX stock price today?

Travere Therapeutics, Inc.'s current stock price is $50.65. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is TVTX bullish or bearish right now?

TVTX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is TVTX's market cap?

TVTX's market cap is $4.79B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is TVTX's current P/E ratio?

TVTX's current P/E ratio is -32.47 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is TVTX's RSI?

TVTX's 14-day RSI is 43.94 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is TVTX above its 50-day and 200-day moving averages?

TVTX is -9.44% from its 50-day SMA and 6.22% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is TVTX's next earnings date?

TVTX's next earnings date is currently listed as Feb 18, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does TVTX pay a dividend?

TVTX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.